TRVI Stock Forecast & Price Target

Trevi Therapeutics has demonstrated promising efficacy with its investigational therapy Haduvio, achieving a 56% placebo-adjusted cough reduction in the Phase 2a RIVER trial, significantly outperforming the 34% reduction seen with a competitor. Financially, the company experienced a narrowing of its fourth quarter net loss to $8.3 million from $11.4 million year-over-year, bolstered by reduced clinical expenses and increased interest income, allowing it to support multiple concurrent trials without immediate financing risks. Furthermore, successful alignment with the FDA for pivotal Phase 3 trials positions Trevi favorably in the market, particularly as it could become the first and only FDA-approved treatment for refractory chronic cough, enhancing its commercial relevance in the broader idiopathic pulmonary fibrosis population.

Trevi Therapeutics Inc. faces significant financial challenges as it continues to incur rising operating expenses associated with the clinical development of Haduvio, leading to a net loss of $42.8 million for FY2025. The company's reported loss of $8.3 million in Q4 2025, along with a disappointing outcome related to its Phase 3 trial program expectations, highlights operational inefficiencies and potential over-reliance on future revenue from an unproven drug. Additionally, despite ending 2025 with $188.3 million in cash, the ongoing increase in general and administrative costs, which rose to $15.9 million, may further strain financial stability and limit available resources for research and development.